Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing
Prolaris added significant information to clinical risk stratification to aid in treatment decision making. Intermediate-risk prostate cancer patients who were recommended to AS by Prolaris were more likely to initially pursue AS and were more likely to remain on AS at 3 years post-diagnosis than patients recommended to DT.
Authors
- Jason Hafron (ORCID: https://orcid.org/0000-0003-0866-797X)
- Paul Yonover
- Alexander Gutin (ORCID: https://orcid.org/0000-0002-6565-3729)
- Todd Matthew Morgan (ORCID: https://orcid.org/0000-0002-1140-0603)
- Chelsea R. Kasten (ORCID: https://orcid.org/0000-0002-6502-1051)
- Wyatt Clegg
- Diana Iliev
- Kevin Cline
- Ronald Tutrone (ORCID: https://orcid.org/0000-0001-6705-778X)
- Jeff S. Jasper
- Alexander DeHaan
- Lauren Lenz (ORCID: https://orcid.org/0000-0003-1957-1068)
- Thomas P. Slavin
- Howard Korman
- Todd Cohen
- Carl A. Olsson
- Robert A. Finch
- Timothy Richardson
Institutions
- Myriad (Germany) (DE)
- Wayne State University (US)
- University of Michigan (US)
- Michigan Institute of Urology (US)
- Geopartner (Poland) (PL)
- Comprehensive Urology (US)
- Regional Urology (US)
- Chesapeake Urology Associates (US)
- Hematology Oncology Consultants (US)
- Wichita Clinic (US)
- Myriad Genetics (US)
- Pratt Institute (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1038/s41391-024-00888-y
- Citations
- 7
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Genomic Health
- Lantheus Medical Imaging
- Myriad Genetics
- Compass Therapeutics
- UroGen Pharma
- Astellas Pharma
- Foundation Medicine
- Janssen Biotech